How Legal THC Created High CBG Strains Of Hemp

By Robert Korczynski

November 13th 2026

Yesterday, November 12th 2026, the federal government of the United States banned any cannabinoids that a Cannabis sativa L. plant cannot naturally produce, including THC-O acetate (both Delta-8-THC-O and Delta-9-THC-O), HHC-O acetate and other synthetic "-O" acetate derivatives, hydrogenated compounds like HHC and H4CBD, oxime cannabinoids (EPN), and any novel designer synthetics that do not exist naturally in cannabis.

And starting December 11th 2026, all naturally occuring trace cannabinoids that are synthesized, isomerized, or converted outside the plant are being banned, including Delta-8 THC, Delta-9 THC, Delta-10 THC, Delta-6a10a, THCP, THCB, THCH, THCV and marketing-blend analogs like THC-JD, THC-X, and PHC.

Also starting December 11th 2026, any finished retail product containing more than 0.4 milligrams of Total THC (including THCA and any other cannabinoids with THC-like effects) per "innermost consumer package" or container is excluded from the federal definition of hemp, which eliminates all intoxicating hemp-derived delta-8 gummies, candies, CBD sodas, seltzers, and vapes unless each individual sub-0.4 mg THC dose is sealed in its own separate inner wrapper.

Since the definition of hemp is just cannabis with less than 0.3% THC in dried flowers, and humans require 10 to 50 times the CBD dose of a dog for arthritis relief, which can cause elevated liver enzymes as well as interfering with the clearance of prescription drugs from the liver if consumed orally, the entire "hemp" industry claims to grow High-CBD hemp, while many are growing High-CBG hemp which is converted into psychoactive cannabinoids like Delta-8-THC to sell in states that do not have legal marijuana.

CBG is called the mother cannabinoid, because it is the precursor chemical that is found in both hemp and marijuana. The only difference between hemp and marijuana is that they produce either THCA synthase or CBDA synthase, which converts the CBGA into THCA or CBDA.

The Pharmaceutical Patent Wall on Clean CBD-to-THC Conversion

Clean, selective, pharmaceutical-grade conversion of CBD into pure delta-9 THC (without generating toxic solvents like methylene chloride or 1,2-dichloroethane, iso-THC, and degraded isomer soups) is locked up behind active chemical process patents held by pharmaceutical and fine-chemical companies—such as Purisys (which holds multiple active U.S. and European patents on high-purity cannabinoid synthesis and cyclization and actively litigates its IP), CCT Sciences (U.S. Patent US12029718B2 for high-purity delta-9 production), and European pharma/extractors like Bionorica / C3 (whose extraction patents were acquired by Canopy Growth and litigated against GW Pharmaceuticals).

Why Gray-Market Labs Couldn't Use It

Unlicensed U.S. hemp processors could not legally license pharmaceutical-grade conversion patents (which require DEA registrations and GMP facilities), and running crude acid-catalyzed CBD cyclization in open reactors produced messy, contaminated delta-8/delta-9 mixtures.

Breeding the "Mother Cannabinoid" Into Existence

Because CBGA is the natural upstream chemical precursor that the plant's own synthase enzymes turn into THCA and CBDA, breeders (most notably Oregon CBD / GTR Seeds) spent years selectively breeding Type IV cannabis lines that knock out the downstream synthase enzymes so the plant accumulates raw CBGA instead of converting it. They released the first commercial high-CBG lines (White CBG and Stem Cell CBG) in 2019–2020, and within a few years pushed stabilized seed lines into the high teens and low 20% CBG range while staying under 0.2%–0.3% Total THC.

Where Does All That High-CBG Biomass Go?

If you walk into a gas station, smoke shop, or dispensary, almost nobody is buying standalone "CBG" products. Retail CBG Is a Tiny Footnote. There is a small niche of online smokable flower vendors (selling strains like White CBG, Stem Cell CBG, Key Lime CBG, and Sourest CBG) and a handful of minor-cannabinoid wellness gummies or tinctures marketed for "daytime focus" or "gut health", usually blended at low ratios alongside CBD or THC. Standalone retail CBG accounts for a tiny fraction of consumer cannabinoid sales.

The Real Destination is Precursor Feedstock for Intoxicating Cannabinoids 

The overwhelming majority of commercial high-CBG acreage is grown as industrial precursor biomass. Because CBGA/CBG sits one step upstream of THC and lacks the structural ring-closure problems of CBD, gray-market labs buy bulk CBG crude and isolate specifically to convert it into psychoactive cannabinoids, or use cloned THCA synthase / CBDA synthase enzymatic bioreactors to turn CBGA directly into THCA/THC without using dirty acid-isomerization chemistry.

Reference List

1. Federal Statutory Ban & Two-Phase Effective Dates (Nov 12, 2026 & Dec 11, 2026) — Public Law 119-37, Section 781 (Enacted Nov. 12, 2025; amending 7 U.S.C. § 1639o to redefine hemp, establish the 0.3% Total THC standard including THCA, exclude non-natural and outside-the-plant synthesized cannabinoids, and cap finished products at 0.4 mg Total THC per innermost container)

Public Law 119-103, Section 2019 (Continuing Appropriations and Extensions Act, 2027, signed Sept. 2, 2026; splitting enforcement so non-plant cannabinoids were banned Nov. 12, 2026, while outside-the-plant conversions and the 0.4 mg per-container cap take effect Dec. 11, 2026)

Smart Approaches to Marijuana (SAM), "Hemp ban, December 11: what changes" (Updated Nov. 12, 2026) 

DJ Holt Law, "Hemp and CBD: The Federal Clock Moved to December 11 for Most Products" (Oct. 20, 2026).

2. Cannabidiol (CBD) Dosing, Bioavailability & Hepatic CYP450 / Liver Enzyme Interactions — Merck Veterinary Manual, "Toxicosis in Dogs and Cats From Cannabidiol (CBD)" (documenting canine oral dosing, low oral bioavailability of 6%–20%, cytochrome P450 metabolism, and serum ALP/liver enzyme elevations)

Frontiers in Veterinary Science & Animals (2024–2025), Canine osteoarthritis dosing protocols (2–5 mg/kg twice daily) and hepatobiliary ALP elevation monitoring.

3. Cannabinoid Biosynthesis (CBGA, THCA Synthase, CBDA Synthase & Chemotype IV) — Journal of Forensic Sciences (2022), "Evaluation of tetrahydrocannabinolic acid (THCA) synthase polymorphisms for distinguishing between marijuana and hemp" (detailing CBGA conversion via THCAS/CBDAS and Chemotype IV CBG-dominant inheritance)

Shoyama et al., Journal of Molecular Biology, Enzymatic cyclization mechanism of cannabigerolic acid (CBGA) to THCA and CBDA.

4. Pharmaceutical Conversion Patents — U.S. Patent US12029718B2 (Assigned to CCT Sciences LLC, granted July 9, 2024), "Process for production of essentially pure delta-9-tetrahydrocannabinol" -Purisys, LLC, cGMP pharmaceutical cannabinoid synthesis and cyclization patent portfolio and DEA-registered manufacturing.

5. Commercial Breeding of High-CBG Cultivars — Oregon CBD / GTR Seeds & Cornell University Hemp Trials (2020), Evaluation and commercial release of Chemotype IV cultivars White CBG and Stem Cell CBG.

Comments

Popular posts from this blog

How Political Islam Conquered The Democrats

An Islamophobia Primer

How SCOTUS Could End Birthright Citizenship